Durable Progression-Free Survival With the Use of BRAF and MEK Inhibitors in Four Cases With V600E-Mutated Gliomas
Introduction BRAF V600 E mutations have been identified in a subset of patients with primary brain tumors. Combination therapy with BRAF and Mitogen-activated protein kinase (MEK) inhibitors (BRAF/MEKi) targeting sequential steps in the MAPK pathway has replaced BRAFi monotherapy as the standard of...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2021-09-01
|
| Series: | Cancer Control |
| Online Access: | https://doi.org/10.1177/10732748211040013 |